NCT05440487 (EXCALIBUR) is a clinical trial of Iron chelator in Chronic Iron Overload, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05440487?

NCT05440487 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05440487?

Interventions in NCT05440487: Iron chelator.

What condition does NCT05440487 study?

NCT05440487 studies Chronic Iron Overload.

Is NCT05440487 still recruiting?

NCT05440487 is currently completed. Last updated 21 October 2022.

Last reviewed 2022-10-21 · How we verify

NCT05440487: EXCALIBUR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload

Completed Last updated 21 October 2022

What this trial tests

trial testing Iron chelator in Chronic Iron Overload in 489 participants. Completed in 29 October 2021.

Timeline

15 September 2015

Primary endpoint
29 October 2021

29 October 2021

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	489
Start date	15 September 2015
Primary completion	29 October 2021
Estimated completion	29 October 2021
Sites	102 locations across Germany

Drugs / interventions tested

Iron chelator

Conditions studied

Chronic Iron Overload — all drugs for Chronic Iron Overload →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Chronic Iron Overload. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter, non-interventional study. Findings are analyzed using epidemiological methods.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms-Real-World Data from the German Noninterventional Study EXCALIBUR.
Schulz F, Hauch U, Ketzler-Henkel S, von der Heyde E, et al · · 2023 · cited 2× · PMID 37892707 · DOI 10.3390/jcm12206569

Verify or expand the search:

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05440487 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 21 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05440487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing